<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>28992985</identifier>
<setSpec>1578-8989</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Casillas-Muñoz, Fidel</dc:author>
<dc:author>Flores-Salinas, Héctor Enrique</dc:author>
<dc:author>Muñoz-Valle, José Francisco</dc:author>
<dc:author>Martínez-Fernández, Diana Emilia</dc:author>
<dc:author>Padilla-Gutiérrez, Jorge Ramón</dc:author>
<dc:author>Valle, Yeminia</dc:author>
<dc:author>Reynoso-Villalpando, Gabriela Lizet</dc:author>
<dc:author>Llamas-Covarrubias, Mara Anaís</dc:author>
<dc:description xml:lang="en">BACKGROUND AND OBJECTIVE Lipid metabolism alterations contribute to acute coronary syndrome (ACS). rs670, rs5070 and rs693 polymorphisms have shown to modify the risk of cardiovascular disease. Apolipoprotein A-I (ApoA-I) plays a major role in reverse cholesterol transport; apolipoprotein B (ApoB) contributes to accumulation of cholesterol in the plaque. The aim of this study was to investigate the association of rs670 and rs5070 polymorphisms of APOA1 and rs693 polymorphism of APOB with ACS and circulating levels of its proteins and find if ApoB/ApoA-I could be implemented as an independent parameter of risk for cardiovascular disease and as a biomarker of lipid-lowering therapy effectiveness in Mexican population. METHODS Three hundred patients with ACS and 300 control subjects (CS) were included. RESULTS Neither genotype nor allele frequencies of rs670, rs5070 and rs693 polymorphisms showed statistical differences between groups. Serum levels of ApoA-I (195 vs. 161.4mg/dL; P&lt;.001) and ApoB (167 vs. 136.9mg/dL; P&lt;.001) were significantly higher in CS compared with ACS; however, there was no genetic association. Unstable angina patients showed the highest ApoA-I levels (males: 176.3mg/dL; females: 209.1mg/dL). CONCLUSION The rs670, rs5070 and rs693 polymorphisms are not genetic susceptibility factors for ACS in Mexican population and had no effect on their apolipoprotein concentrations. In our population, ApoA-I, ApoB and HDL-C could be better biomarkers of cardiovascular risk and could indicate if statins doses reduce atherogenic particles properly.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Apolipoprotein B</dc:subject>
<dc:subject>Síndrome coronario agudo</dc:subject>
<dc:subject>Riesgo aterogénico</dc:subject>
<dc:subject>Apolipoprotein AI</dc:subject>
<dc:subject>Atherogenic risk</dc:subject>
<dc:subject>Apolipoproteína AI</dc:subject>
<dc:subject>Tratamiento de reducción de lípidos</dc:subject>
<dc:subject>Acute coronary syndrome</dc:subject>
<dc:subject>Lipid-lowering therapy</dc:subject>
<dc:subject>Apolipoproteína B</dc:subject>
<dc:date>2017 Oct 06 </dc:date>
<dc:title xml:lang="es">Polimorfismos de los genes APOA1 y APOB y concentraciones de sus apolipoproteínas como biomarcadores de riesgo en el síndrome coronario agudo: relación con la efectividad del tratamiento hipolipemiante.</dc:title>
<dc:title xml:lang="en">APOA1 and APOB polymorphisms and apolipoprotein concentrations as biomarkers of risk in acute coronary syndrome: Relationship with lipid-lowering therapy effectiveness.</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
